ACTRN12606000168550尚未招募4 期
PreFER MVP For Elective Replacement: Previously paced patients, coming in For Elective Replacement, using MVP (Managed Ventricular Pacing): to demonstrate the benefit of MVP in pacemaker and implantable carvioverter defibrillator (ICD) patients with a history of right ventricular pacing. The MVP function reduces unnecessary right ventricular pacing which has been shown to induce heart failure. Total mortality and heart failure hospitalization will be evaluated.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 801
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Patient with dual chamber pacemaker or ICD, paced for at least 2 years, who are due for a replacement of their device, male or female, who have signed the consent form or have a legal guardian willing to sign the consent form.
排除标准
- •Patient with cardiac resynchronization therapy indications, or permanent atrial fibrillation, or permanent atrioventricular block.
研究者
相似试验
已完成
不适用
Study of Default Options in Advance DirectivesCOPDSevere or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen TherapyOther Interstitial Lung Disease Without Curative TherapyNYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past YearMalignancyAny Stage 3B or 4 Solid TumorIdiopathic Pulmonary FibrosisCongestive Heart FailureNCT01817686Corporal Michael J. Crescenz VA Medical Center62
已完成
3 期
REPRISE III: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus* Valve System - Randomized Clinical EvaluatioNL-OMON44639Boston Scientific Cooperation International20
招募中
4 期
Study to assess the Safety and efficacy of Hetero tenecteplase in the treatment of Myocardial infarction.CTRI/2024/03/063694Hetero Biopharma Limited
招募中
4 期
An open label, multi-center, Phase IV rollover protocol to evaluate long term safety dataindications including but not limited to myelofibrosis (MF), polycythemia vera (PV), acute Graft vs Host Disease (aGvHD) or chronic Graft vs Host Disease (cGvHD).JPRN-jRCT2080225007ovartis Pharma. K.K.356
进行中（未招募）
1 期
A study for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589) combination study and are judged by the investigator to benefit from continued treatmentThis roll-over study is designed to accept patients with varied disease origins. Please refer to the parent protocol for the disease background information and rationale for use of ruxolitinib in their individual indications.MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066262Term: Acute graft versus host disease in skinSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066263Term: Acute graft versus host disease in liverSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10072160Term: Chronic graft versus host disease in liverSystem OrganEUCTR2014-003527-22-PLovartis Pharma Services AG366